Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (241-250 of 344) with videos related to

Pageof 35
Sort By:
Cancer Research Communications|September 25, 2025
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter StudyKohei Shitara, Motohiro Tamiya, Kyoichi Okishio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline UpdateManish A Shah, Erin B Kennedy, Dana Deighton, et al.
Molecular Cancer Therapeutics|January 26, 2019
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid TumorsAkihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis, Koji Oba, Xavier Paoletti, et al.
JAMA Oncology|October 11, 2019
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical TrialDavid H Ilson, Josep Tabernero, Aliaksandr Prokharau, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 7, 2026
Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trialsKensei Yamaguchi, Hirokazu Shoji, Hisateru Yasui, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2019
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trialYasuhide Yamada, Narikazu Boku, Junki Mizusawa, et al.
Future Oncology (London, England)|February 20, 2019
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancerYung-Jue Bang, Eric Van Cutsem, Charles S Fuchs, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trialKohei Shitara, Atsuo Takashima, Kazumasa Fujitani, et al.
The Journal of Pathology|February 21, 2025
PI3 expression predicts recurrence after chemotherapy with DNA-damaging drugs in gastric cancerKenji Harada, Naoya Sakamoto, Takumi Kitaoka, et al.
Pageof 35

Showing results (241-250 of 344) with videos related to

Sort By:
Pageof 35
Cancer Research Communications|September 25, 2025
Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1-Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter StudyKohei Shitara, Motohiro Tamiya, Kyoichi Okishio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2026
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline UpdateManish A Shah, Erin B Kennedy, Dana Deighton, et al.
Molecular Cancer Therapeutics|January 26, 2019
First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid TumorsAkihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 29, 2013
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis, Koji Oba, Xavier Paoletti, et al.
JAMA Oncology|October 11, 2019
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical TrialDavid H Ilson, Josep Tabernero, Aliaksandr Prokharau, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 7, 2026
Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trialsKensei Yamaguchi, Hirokazu Shoji, Hisateru Yasui, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2019
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trialYasuhide Yamada, Narikazu Boku, Junki Mizusawa, et al.
Future Oncology (London, England)|February 20, 2019
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancerYung-Jue Bang, Eric Van Cutsem, Charles S Fuchs, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trialKohei Shitara, Atsuo Takashima, Kazumasa Fujitani, et al.
The Journal of Pathology|February 21, 2025
PI3 expression predicts recurrence after chemotherapy with DNA-damaging drugs in gastric cancerKenji Harada, Naoya Sakamoto, Takumi Kitaoka, et al.
Pageof 35